Aventis Pharma Articles
Court rules in novel False Claims Act case where one pharma firm sues another viewed by HP&M lawyer
28 April 2013
Big pharma struggles to benefit from increased CVD drug usage in market set to grow to $107 billion in 2018
3 March 2010
Mixed fortunes for Roche’s Avastin; Xeloda recommended by EU
26 February 2010
While weakening of Mexico’s peso is causing problems, generics will fuel pharma market growth
25 February 2010
Europe’s CHMP backs Sanofi Pasteur’s Humenza and GSK’s Votrient; gives opinions on other products
22 February 2010
AstraZeneca’s CEO defends company’s stance in Bloomberg interview
15 February 2010
BioSquare meeting identifies future trends, including patient-centered therapy and end to the blockbuster model
12 February 2010
Sanofi-Aventis 2009 EPS leaps 18% but slows in 4th quarter; in line with expectations
10 February 2010
Poland’s pharma distribution seeing many changes, with significant consolidation among wholesalers
9 February 2010
GSK launches new specialist rare diseases R&D unit; names new president for GSK Japan
5 February 2010
Burst of M&A activity in pharma during 2009 led by mega-deals from Pfizer/Wyeth and Merck & Co/S-P
4 February 2010
Pharmaceutical M&A deals in 2009
4 February 2010
Belgium’s UCB to maximize US focus and resources on core products, hiving off primary care to Sanofi and Teva
1 February 2010
Sanofi-Aventis sets sights in China’s dynamic consumer health care market via JV with Minsheng
1 February 2010
Uptake of the first oral MS therapies will result in the market value peaking at $8.4 billion in 2013
1 February 2010
Bristol-Myers Squibb forecasts large jump in 2010 profit to range of $1.94 to $2.04 per share
29 January 2010
AstraZeneca to cut another 8,000 jobs as part of $1.8 billion cost-cutting program; unveils new R&D model
29 January 2010
Republican victory in Massachusetts a blow for Obama health reform plans; not a happy first anniversary present
20 January 2010
Teva, Pfizer and EQT among final three bidders for Ratiopharm
19 January 2010
WHO’s pandemic advisor strongly denies industry influence in “false flu pandemic fiasco;” GSK says same
18 January 2010
EU action on pharma patent “pay-to-delay” settlements - a legal opinion; US FTC also to review the subject
13 January 2010
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
UK govt in talks with GlaxoSmithKline to offload swine flu vaccine stocks as pandemic fails to materialize
11 January 2010
Pfizer makes another move into generics in deal with Strides Arcolab; enters into discovery accord with Ensemble
7 January 2010
Indian Health Ministry bans obesity drug rimonabant following reports of side effects; TB drug curb moves “a failure”
4 January 2010
Draft guidance from UK’s NICE unable to recommend Sanofi-Aventis’ Multaq for atrial fibrillation
24 December 2009
Sanofi-Aventis to buy consumer health firm Chattem for $1.9 billion, aiming for bigger role in OTC
22 December 2009
Sanofi-Aventis pulls out of deal with AEterna Zentaris on Cetrorelix in benign prostatic hyperplasia
21 December 2009
Roche/Ipsen’s taspoglutide meets Ph III primary endpoints against Lantus and placebo in patients with high BMI
18 December 2009
Sanofi Pasteur expands C. difficile study into USA; gets rights to MRSA agent; parent withdraws few batches of pediatric H1N1 vaccine
16 December 2009
Atrial fibrillation drug market to grow more than sevenfold, to $6.1 billion in 2018
16 December 2009
European Commission confirms further surprise inspections in the pharmaceutical sector
10 December 2009
Sanofi-Aventis enters up to $375 million superbug antibody deal with Alopexx; Pasteur moves on Dengue fever
10 December 2009
Generic erosion will bite into the acute coronary syndrome market, cutting sales nearly 10% from 2008 to 2018
8 December 2009
Sanofi-Aventis gains US/Canada Rights to novel epinephrine auto-injector from Intelliject for up to $230 million
1 December 2009
Sanofi-Aventis to reinforce its presence in Russia via the ”Pharmpolis Project;” Multaq approved by EC
30 November 2009
Generics will continue to dominate Central and Eastern European pharma markets until 2011
30 November 2009
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
24 November 2009
Sanofi-Aventis CEO rules out more big acquisitions, in FT interview
23 November 2009
AstraZeneca presents strong Ph II results for Brilinta at AHA, beating Plavix; files drug with FDA
19 November 2009
US FDA warns against use of PPI Prilosec with Plavix
18 November 2009
GSK and Nabi in deal for NicVAX, with upfront and potential payments of over $500 million
17 November 2009
Bristol-Myers Squibb decides to split off Mead Johnson nutritional unit to concentrate on biopharma
17 November 2009
PhRMA proposes FDA-approved logo for link to patient info on-line
16 November 2009
Nycomed reports satisfactory 3rd-quarter 2009 performance, despite generic erosion of pantoprazole sales
13 November 2009
Several bidders line up for Germany’s Ratiopharm
12 November 2009
Sanofi-Aventis announces changes to executive committee
3 November 2009
Sanofi-Aventis says strong swine flu vaccine sales in 4th quarter will drive higher earnings
30 October 2009
Batch of approvals and positive opinions from EU’s CHMP
26 October 2009
One time gain triples Merck & Co’s 3rd quarter 2009 earnings, beating forecasts; EU clears S-P deal
23 October 2009
Global H1N1 2009 flu vaccine market worth $ 7.03 billion by 2011
23 October 2009
Wellstat could earn $350 million from Sanofi-Aventis deal for novel type 2 diabetes age
21 October 2009
Swine flu vaccine shortage likely in the USA
19 October 2009
Biosimilar insulins and analogs set to erode $6.1 billion in brand sales in the USA and Europe by 2018
15 October 2009
Seattle Genetics hires new commercial chief, promotes legal exec
14 October 2009
Canada’s QLT sells US unit to TOLMAR for up to $230 million; aims to concentrate to ocular therapy
2 October 2009
Sanofi-Aventis’ latest shopping spree includes France’s Fovea and deal with Merrimack
1 October 2009
EU Commissioner Kroes still gunning for Pharma
30 September 2009
Sanofi-Aventis launches major insulin research program; updates on rimonabant court case
30 September 2009
Sanofi Aventis' Multaq recommended for approval in the EU
28 September 2009
BIO-Europe 2009: an opportunity to hunt for deals
25 September 2009
Experimental HIV vaccine cuts infection
24 September 2009
VEM agrees to sell Ratiopharm; large number of interested parties
19 September 2009
Sanofi-Aventis’ Ciltyri delayed as FDA wants more info
17 September 2009
US FDA approves vaccines for 2009 H1N1 influenza virus
16 September 2009
Sanofi-Aventis and Regeneron discontinue one Ph III study of aflibercept
14 September 2009
US CDER chief under investigation over conflict of interest
13 September 2009
Sanofi-Aventis’ otamixaban substantially reduced complications of invasive management of acute coronary syndromes
1 September 2009
Romania’s Pharma market set to grow at 9% CAGR
1 September 2009
US FDA clears UCB/Sanofi-Aventis’ Xyzal for children
25 August 2009
Bristol-Myers Squibb says USPTO to review Plavix patent
20 August 2009
Indian patent law changes will benefit Pharma multinationals
19 August 2009
AEterna Zentaris plunges as cetrorelix misses study endpoint
18 August 2009
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
